TRICARE Wegovy and Zepbound Coverage: What Military Families Need to Know

TRICARE now covers Wegovy (semaglutide injection) and Zepbound (tirzepatide injection) for chronic weight management if you meet the Defense Health Agency’s clinical criteria and your prescriber submits-and wins-a prior authorization. Coverage is limited to Prime, Select and related plans, excludes TRICARE For Life, and comes with a 100 % patient cost-share, meaning you still pay the full pharmacy price even after approval (tricare.mil). Understanding these rules, gathering the right documentation upfront and knowing the fallback savings programs can keep you from weeks of avoidable denials.

• More than half of active-duty service members are overweight and 27 % meet criteria for obesity (Corrado et al., 2026).
• TRICARE began covering Wegovy and Zepbound for weight loss across most non-Medicare plans on September 1, 2024, with manual prior-authorization criteria (health.mil).
• Approval requires a BMI ≥30 kg/m² or ≥27 kg/m² with at least one weight-related condition, plus documented failure or intolerance of step-therapy drugs such as phentermine (health.mil).
• Even after approval, beneficiaries pay 100 % of the drug’s price-currently $1,349 per package for Wegovy (novocare.com) and $299-$699 per month for Zepbound, dose-dependent (zepbound.lilly.com).
• TRICARE For Life does not cover weight-loss GLP-1s, but eligible Medicare members can access them through the new Medicare GLP-1 Bridge Program (tricare.mil).
• Manufacturer savings cards, LillyDirect® and NovoCare® self-pay offers can drop out-of-pocket costs to $25-$449 a month for commercially insured or cash-pay patients.

TRICARE coverage means clinical approval, not a paid benefit

TRICARE lists Wegovy and Zepbound as Uniform Formulary, non-formulary drugs that require manual prior authorization. If the request is approved, the prescription can be dispensed through retail network pharmacies, mail-order home delivery, or certain military treatment facility (MTF) outpatient pharmacies. However, TRICARE assigns these agents to the “Tier: Patient Pays” bucket, so beneficiaries pay the full negotiated pharmacy price with no cost-share offset (tricare.mil).

Practically, that transforms the benefit from a payment benefit to an access authorization: TRICARE verifies medical necessity but does not subsidize the medication. Understanding that distinction keeps expectations realistic and guides budget planning from day one.

You qualify only if you meet BMI and step-therapy requirements

Every new Wegovy or Zepbound request must satisfy the Defense Health Agency’s manual prior-authorization checklist. Key points include (health.mil):

Eligibility snapshot:

• Age ≥ 18 years (Wegovy extends to ages 12-17 under separate pediatric criteria).
• BMI ≥ 30 kg/m² or BMI ≥ 27 kg/m² plus at least one comorbidity such as hypertension, pre-diabetes, dyslipidemia, obstructive sleep apnea, or coronary artery disease.
• Step therapy proof: Documented trial, intolerance, or contraindication to at least one inexpensive stimulant weight-loss drug (phentermine, benzphetamine, diethylpropion, or phendimetrazine).
• Diabetes caveat: If the patient also has type 2 diabetes, they must have previously tried metformin and the DHA-preferred GLP-1 dulaglutide (Trulicity).
• Exclusions: Pregnancy, family or personal history of medullary thyroid carcinoma (MTC) or MEN 2, chronic malabsorption, and use of any other GLP-1 at the same time.
• Renewal rule: The first PA lasts four months; renewal requires ≥ 5 % weight loss (≥ 4 % for adolescents) plus ongoing diet and lifestyle counseling.

Prior-authorization paperwork: how to get it right the first time

Approvals hinge on the detail and timing of the paperwork your prescriber submits through Express Scripts. Skipping one checkbox is the fastest way to a denial. Follow these best practices:

Gather objective evidence: Download your last three weight and BMI entries from MHS Genesis or your fitness tracker and include blood-pressure or sleep-apnea documentation.

Attach step-therapy proof: Pharmacy records or a note detailing intolerance to phentermine meet the DHA step-therapy rule. A blanket statement like “patient refused” will be rejected.

Detail lifestyle counseling: The DHA wants documentation of ongoing diet and exercise efforts; attach a referral to base nutrition services or completion of a weight-management class.

Use the correct form: Express Scripts’ “Weight Loss Agents PA” form auto-populates ICD-10 codes and dates; outdated forms often stall in review queues.

Check status proactively: Express Scripts updates the electronic PA dashboard within 48 hours of receipt; call if you do not see movement in three business days.

What Wegovy and Zepbound cost when TRICARE pays 0 %

Because TRICARE places these drugs in a patient-pays tier, your out-of-pocket cost equals the pharmacy’s cash price. List prices and manufacturer self-pay programs are below.

Alternatives and next steps when TRICARE denies or you cannot afford it

Appeal quickly: TRICARE allows one level of appeal for pharmacy denials. Submit new clinical data-especially comorbidity documentation and step-therapy failures-within 90 days.

Request a medical-necessity waiver: If you cannot tolerate mandated step-therapy drugs (for example, stimulant appetite suppressants increase blood pressure), your prescriber can file a medical-necessity statement, which often overturns first-round denials.

Use manufacturer programs while you wait: Activate the Wegovy or Zepbound savings card before you reach the pharmacy counter so the claim automatically applies the discount.

Compare retail cash prices: If you choose to pay cash, print a free prescription discount card and compare prices at your local pharmacy. Discounts can shave 10-25 % off the list price on certain doses.

For more tactics, see our step-by-step insurance appeal guide for Zepbound and what to do when your PA is denied.